

JUL 26 2000

K001982

SUMMARY OF SAFETY AND EFFECTIVENESS

NAME OF FIRM: DePuy Orthopaedics, Inc.
P.O. Box 988
700 Orthopaedic Drive
Warsaw, IN 46581-0988

510(k) CONTACT: Arlene C. Saull, RAC
Senior Regulatory Associate

TRADE NAME: Tri-Lock® Hip Stem

COMMON NAME: Hip prosthesis

CLASSIFICATION: 888.3358 Hip joint metal/polymer semi-constrained cementless prosthesis

DEVICE PRODUCT CODE: 87 LPH Prosthesis, hip, semi-constrained, metal/polymer, porous uncemented

SUBSTANTIALLY EQUIVALENT DEVICES: Tri-Lock® Hip Stem, cleared via 510(k) on 03-18-98

DEVICE DESCRIPTION AND INTENDED USE:

The Tri-Lock Hip Stem is porous coated and intended for cementless use in total hip arthroplasty.

Total hip arthroplasty is intended to provide increased patient mobility and reduce pain by replacing the damaged hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components. Total hip replacement is indicated in the following conditions:

1. A severely painful and/or disabled joint from osteoarthritis, traumatic arthritis, rheumatoid arthritis, or congenital hip dysplasia.
2. Avascular necrosis of the femoral head.
3. Acute traumatic fracture of the femoral head or neck.
4. Failed previous hip surgery including joint reconstruction, internal fixation, arthrodesis, hemiarthroplasty, surface replacement arthroplasty, or total hip replacement.
5. Certain cases of ankylosis.

The Tri-Lock Hip Stem is part of a modular system for use in total hip replacement. The femoral component is provided as two separate units, a porous coated femoral hip stem manufactured from ASTM F-75 CoCr and a modular head also manufactured from ASTM F-75 CoCr, which locks onto the femoral hip stem. The modular head articulates with an acetabular cup of an appropriate diameter.

BASIS OF SUBSTANTIAL EQUIVALENCE:

The Tri-Lock Hip Stem has the following similarities to the previously cleared Tri-Lock Hip Stems that were cleared in 1998; same intended use; same material; same method of manufacture; same design; same sterilization and packaging methods. The Tri-Lock Hip Stem demonstrated adequate performance in design control activities.

000003



JUL 26 2000

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Ms. Arlene C. Saull, RAC
Senior Regulatory Associate
Depuy Orthopaedics Incorporated
P.O. Box 988
700 Orthopaedic Drive
Warsaw, Indiana 46581-0988

Re: K001982
Trade Name: Tri-Lock 6.3 mm Hip Stem
Regulatory Class: II
Product Code: LPH
Dated: February June 23, 2000
Received: June 29, 2000

Dear Ms. Saull:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general control provisions of the Act. The general control provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2 - Ms. Arlene C. Saull, RAC

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597, or at its Internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,


Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative and
Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known) K001982

Device Name: Tri-Lock® Hip Stem

Indications for Use:

Total hip arthroplasty is intended to provide increased patient mobility and reduce pain by replacing the damaged hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components. Total hip replacement is indicated in the following conditions:

1. A severely painful and/or disabled joint from osteoarthritis, traumatic arthritis, rheumatoid arthritis, or congenital hip dysplasia.
2. Avascular necrosis of the femoral head.
3. Acute traumatic fracture of the femoral head or neck.
4. Failed previous hip surgery including joint reconstruction, internal fixation, arthrodesis, hemiarthroplasty, surface replacement arthroplasty, or total hip replacement.
5. Certain cases of ankylosis.

Concurrence of CDRH, Office of Device Evaluation:

Danna P. Lochner.
(Division Sign-Off)
Division of General Resorativ
510(k) Number K001982

Prescription Use OR Over-The Counter Use (Per 21 CFR 801.109)

000004